BriOri Biotech is developing topical Vioxx (Rofecoxib) for the treatment of osteoarthritis (OA). BriOri Biotech announced that on March 1, 2022 that it had been issued a patent covering topical formulations of Vioxx and combinations with other drugs. BriOri is currently scheduling Regulatory Toxicity studies for Q3 2022. A clinical trial is planned for Q2 2023. The company's founders represent the original Merck team that brought Vioxx to the market and were also instrumental in bringing Voltaren and Pennsaid to the market.
More than 23 million Americans suffer from OA and approximately 30% do not respond to the few topical NSAIDs that are on the market. Vioxx is the most powerful NSAID and as a topical formulation exhibits more than a 660-fold improved therapeutic index compared to oral dosages. BriOri is currently seeking investors and licensees.
More than 23 million Americans suffer from OA and approximately 30% do not respond to the few topical NSAIDs that are on the market. Vioxx is the most powerful NSAID and as a topical formulation exhibits more than a 660-fold improved therapeutic index compared to oral dosages. BriOri is currently seeking investors and licensees.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
Vioxx
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
